Arvelle Therapeutics
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
* | N/A | Corporate spinout | |
* | $180m | Series A | |
* | $42.7m | Series A | |
$960m Valuation: $960m | Acquisition | ||
| Total Funding | €202m | ||
Recent News about Arvelle Therapeutics
EditArvelle Therapeutics International GmbH, based in Zug, Switzerland, is a biopharmaceutical company focused on developing and commercializing innovative treatments for central nervous system (CNS) disorders. The company's primary product is cenobamate, an investigational anti-seizure medication aimed at treating drug-resistant focal onset seizures in adults. This medication has been designated as a Promising Innovative Medicine (PIM) by the UK's Medicines and Healthcare products Regulatory Agency (MHRA).
Arvelle operates in the European healthcare market, targeting patients suffering from CNS disorders, particularly those with epilepsy who have not responded well to existing treatments. The company collaborates with healthcare professionals (HCPs) and partners like Durbin to ensure the distribution and accessibility of their medication across Europe.
Arvelle's business model revolves around the development, regulatory approval, and commercialization of cenobamate. They generate revenue through the sale of this medication to healthcare providers and institutions. By focusing on a niche market with significant unmet medical needs, Arvelle aims to establish a strong presence in the CNS disorder treatment landscape.
The company actively participates in industry conferences, such as the Jefferies Virtual 2020 Healthcare Conference and the Jefferies 2020 London Healthcare Conference, to present their progress and engage with potential investors and partners. These activities help Arvelle to build credibility and attract the necessary funding to support their ongoing research and development efforts.
In summary, Arvelle Therapeutics is dedicated to bringing new hope to patients with CNS disorders through innovative treatments like cenobamate. Their strategic partnerships and focus on a specialized market position them as a promising player in the biopharmaceutical industry.
Keywords: CNS disorders, epilepsy, anti-seizure medication, cenobamate, European market, biopharmaceutical, drug-resistant seizures, healthcare professionals, innovative treatments, regulatory approval.